News
2008 Office Hour Changes |
12/01/2008
At times it is necessary for us to make adjustments to our scheduled hours. When we need to make changes we will post them here on our web site.
At times it is necessary for us to make adjustments to our scheduled hours. When we need to make changes we will post them here on our web site.
Mast Cell Tumor Study |
11/30/2008
The New England Veterinary Oncology Group is pleased to announce participation in a clinical trial investigating a novel formulation of a taxol chemotherapeutic compared to single agent CeeNu (lomustine) for the treatment of grade II/III cutaneous mast cell tumors in dogs.
The New England Veterinary Oncology Group is pleased to announce participation in a clinical trial investigating a novel formulation of a taxol chemotherapeutic compared to single agent CeeNu (lomustine) for the treatment of grade II/III cutaneous mast cell tumors in dogs.
Emergency on call for active patients |
08/21/2008
NEVOG is pleased to announce that we are now offering an on-call after hours emergency service. At this time, this service is being offered on a trial basis. The goal of this service is to help make recommendations in emergency situations. A NEVOG clinician will be available by phone to offer advice and if needed, direct you to the appropriate emergency facility. We will also be able to consult with an emergency clinician if it is recommended that your pet be seen.
NEVOG is pleased to announce that we are now offering an on-call after hours emergency service. At this time, this service is being offered on a trial basis. The goal of this service is to help make recommendations in emergency situations. A NEVOG clinician will be available by phone to offer advice and if needed, direct you to the appropriate emergency facility. We will also be able to consult with an emergency clinician if it is recommended that your pet be seen.
Osteosarcoma Study |
08/21/2008
NEVOG is announcing the availability of a partially funded prospective clinical trial evaluating the use of Carboplatin and Gemzar (Gemcitabine) chemotherapy in the post amputation treatment of canine appendicular osteosarcoma.
NEVOG is announcing the availability of a partially funded prospective clinical trial evaluating the use of Carboplatin and Gemzar (Gemcitabine) chemotherapy in the post amputation treatment of canine appendicular osteosarcoma.
Pet Friendly Hotels |
11/23/2007
We are often asked if there are pet friendly hotels in the area. While we do know of some hotels that are designated as pet friendly our list is not 100% comprehensive.
We are often asked if there are pet friendly hotels in the area. While we do know of some hotels that are designated as pet friendly our list is not 100% comprehensive.
N.E.V.O.G. is now seeing patients in N.H. |
01/03/2007
The New England Veterinary Oncology Group LLP (NEVOG) the only private, full service, veterinary oncology care center in New England based in Waltham MA, is now seeing patients at the Center for Advanced Veterinary Care (AVC) in Manchester NH. Drs. Kim Cronin, Jeff Philibert, and Sheri Siegel bring to Manchester, NH the same high quality and compassionate care for which NEVOG is known.
The New England Veterinary Oncology Group LLP (NEVOG) the only private, full service, veterinary oncology care center in New England based in Waltham MA, is now seeing patients at the Center for Advanced Veterinary Care (AVC) in Manchester NH. Drs. Kim Cronin, Jeff Philibert, and Sheri Siegel bring to Manchester, NH the same high quality and compassionate care for which NEVOG is known.
Kari Rosen, SVM